Myostatin has both local and endocrine effects that can link sarcopenia and NAFLD via a complex process involving several cellular signaling pathways, resulting in the downregulation of the expression of myogenic factors, the decrease in protein synthesis, and the activation of proteasome–ubiquitin ligases (5, 115). Here, MSTN is linked to metabolic dysfunction-associated steatotic liver disease.